Compare GAIN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAIN | CTMX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.3M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | GAIN | CTMX |
|---|---|---|
| Price | $14.23 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $14.75 | $11.90 |
| AVG Volume (30 Days) | 348.1K | ★ 9.4M |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | ★ 10.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.32 | $27.22 |
| P/E Ratio | ★ $4.38 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.42 | $0.40 |
| 52 Week High | $15.25 | $8.21 |
| Indicator | GAIN | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 44.37 |
| Support Level | $13.69 | $3.55 |
| Resistance Level | $14.57 | $6.20 |
| Average True Range (ATR) | 0.35 | 0.60 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 80.00 | 3.23 |
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.